CorMedix (CRMD) Granted Extension of NYSE MKT Listing
4/22/2013 12:52:54 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, received a notice from the NYSE MKT that the NYSE-MKT has accepted CorMedix’s plan to regain compliance with Section 1003(a)(iv) of the continued listing standards of the NYSE-MKT and granted CorMedix an extension until June 30, 2013 to regain compliance.
Help employers find you! Check out all the jobs and post your resume.
comments powered by